Evidence map›Paper›PMID 38765016›Full record

ArticleFrontiers in immunology2024

Case report: BTK inhibitors is effective in type II mixed cryoglobulinemia with wild-type MyD88.

Mingyue Xu, Yunyu Xu, Li Yuan, Da Shang, Ruiying Chen, Shaojun Liu, Yan Li, Aiping Liu, Ruilai Liu, Qian Wang and 3 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mingyue Xu *Division of Nephrology, Huashan Hospital, Fudan University, Shanghai, China.
Yunyu Xu *Division of Nephrology, Huashan Hospital, Fudan University, Shanghai, China.
Li Yuan *Division of Nephrology, Huashan Hospital, Fudan University, Shanghai, China.
Da ShangDivision of Nephrology, Huashan Hospital, Fudan University, Shanghai, China.
Ruiying ChenDivision of Nephrology, Huashan Hospital, Fudan University, Shanghai, China.
Shaojun LiuDivision of Nephrology, Huashan Hospital, Fudan University, Shanghai, China.
Yan LiDivision of Nephrology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, China.
Aiping LiuClinical Laboratory of Huashan Hospital, Fudan University, Shanghai, China.
Ruilai LiuClinical Laboratory of Huashan Hospital, Fudan University, Shanghai, China.
Qian WangDivision of Hematology, Huashan Hospital, Fudan University, Shanghai, China.
Tianling DingDivision of Hematology, Huashan Hospital, Fudan University, Shanghai, China.
Qionghong XieDivision of Nephrology, Huashan Hospital, Fudan University, Shanghai, China.
Chuan-Ming HaoDivision of Nephrology, Huashan Hospital, Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study presents two cases of type II mixed cryoglobulinemia. One case is essential, while the other is presumably associated with hepatitis B virus (HBV) infection. Both patients tested positive for monoclonal IgMκ, but negative for MyD88 mutation. They showed resistance to rituximab combined with a glucosteroid regimen, but responded positively to BTK inhibitors. These cases highlight the remarkable effectiveness of BTK inhibitors in treating refractory type II cryoglobulinemia without MyD88 mutation. The first patient achieved rapid complete remission of nephrotic syndrome within one month of starting ibrutinib, along with a significant reduction in cryoglobulin levels and abnormal clonal cells. The second patient had a rapid disappearance of rash within three days and accelerated wound healing within one week of initiating orelabrutinib, accompanied by a reduction in C-reactive protein. However, there was no reduction in cryoglobulin levels during the 12-month follow-up. These findings suggest varied mechanisms of action of BTK inhibitors in type II cryoglobulinemia through different mechanisms.

Indexed as

Agammaglobulinaemia Tyrosine KinaseCryoglobulinemiaMyeloid Differentiation Factor 88Protein Kinase InhibitorsAdenineAgedFemaleHumansMaleMiddle AgedPiperidinesTreatment OutcomeAdenineAgammaglobulinaemia Tyrosine KinaseBTK protein, humanibrutinibMYD88 protein, humanMyeloid Differentiation Factor 88PiperidinesProtein Kinase InhibitorsBTK inhibitorshepatitis B virusibrutinibMyD88 mutationorelabrutinibtype II cryoglobulinemia

Identifiers

PMID38765016
PMCPMC11099222

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.